Please assess the completion status of the following clinical trial:

Trial Title: Effects of cKit Inhibition by Imatinib in Patients With Severe Refractory Asthma (KIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients 18-65 years of age, diagnosed with asthma for at least 1 year;~2. Refractory asthma, defined as reporting that their asthma has not been completely controlled in the past 3 months despite continuous treatment with high-dose inhaled corticosteroids (ICS) and an additional controller medication, with or without continuous oral corticosteroids (OCS)~Exclusion Criteria:~1. Current smoking or smoking history of greater than 10 pack-years~2. Any other significant respiratory or cardiac disease, or the presence of clinically important comorbidities, including uncontrolled diabetes, uncontrolled coronary artery disease~3. If subject cannot undergo bronchoscopy procedure due to safety reasons~4. Previous treatment with Imatinib~5. A history of acute heart failure or chronic left sided heart failure~6. Uncontrolled systemic arterial hypertension~7. History of major bleeding or intracranial hemorrhage~8. History of immunodeficiency diseases, including HIV~9. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer~10. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.~11. Diagnosis of Hepatitis B or C.~12. History of alcohol abuse within 6 months of screening.~13. History of illicit drug abuse within 6 months of screening.~14. Regular use of anticoagulants (eg: Warfarin Sodium, Coumadin), amiodarone, carbamazepine, Cyclosporine, Rifampicin, or reverse transcriptase inhibitors

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Imatinib mesylate (Type: ACTIVE_COMPARATOR): Group on active imatinib treatment
- Placebo (Type: PLACEBO_COMPARATOR): Group on Placebo treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).